目的 對2019—2021年天津市人民醫(yī)院貝伐珠單抗的臨床應(yīng)用情況進(jìn)行評價，以期促進(jìn)貝伐珠單抗超說明書用藥的管理及其臨床合理應(yīng)用。方法 回顧性分析天津市人民醫(yī)院2019年1月—2021年12月使用貝伐珠單抗患者的用藥信息，根據(jù)說明書及指南評價其應(yīng)用的合理性。結(jié)果 共收集1 313例患者（6 134次醫(yī)囑），通過適應(yīng)癥、治療方案、用法用量3個方面評價應(yīng)用合理性。結(jié)果 顯示，存在適應(yīng)癥不適宜情況占比0.07%，用法用量不適宜情況占比4.77%，其中包括給藥濃度不適宜（1.21%）、給藥途徑不適宜（0.23%）、與手術(shù)間隔時間不適宜（3.33%）。結(jié)論 天津市人民醫(yī)院貝伐珠單抗的臨床應(yīng)用基本符合國內(nèi)外說明書及指南要求，但也存在一定的超說明書用藥情況。醫(yī)院及臨床藥師應(yīng)持續(xù)規(guī)范抗腫瘤藥物超說明書使用的管理，促進(jìn)抗腫瘤藥物的合理應(yīng)用。

Objective To evaluate the clinical application of bevacizumab in Tianjin Union Medical Center from 2019 to 2021, in order to promote the management of off-label use of bevacizumab and its rational clinical application. Methods The medication information of patients receiving bevacizumab from January 2019 to December 2021 in Tianjin Union Medical Center was retrospectively analyzed, and the rationality of its application was evaluated according to the instructions and guidelines. Results A total of 1 313 patients (6 134 times of medical advice) were collected to evaluate the rationality of application in three aspects:indication, treatment plan, usage and dosage. The results showed that unsuitable indications accounted for 0.07%, unsuitable usage and dosage accounted for 4.77%, including unsuitable concentration (1.21%), unsuitable route of administration (0.23%), and unsuitable interval time with operation (3.33%). Conclusion The clinical application of bevacizumab in Tianjin Union Medical Center basically met the requirements of domestic and foreign instructions and guidelines, but there were some cases of off-label drug use. Hospitals and clinical pharmacists should continue to standardize the management of off-label use of antineoplastic drugs to promote rational use of antineoplastic drugs.

R979.1